Brief: Amicus Therapeutics Q1 Revenue USD 110.4 Million Vs. IBES Estimate USD 111.2 Million
May 09 (Reuters) - Amicus Therapeutics Q1 EPS USD -0.16. * Q1 adjusted operating expenses USD 85.6 million * Q1 operating expenses USD 124.6 million * Q1 net income USD -48.4 million
Recent news on Amicus Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT CONTINUES TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Amicus Q4 revenue beats estimates